Feb 12 (Reuters) - CSL Ltd (CSL) :
- TOP-LINE RESULTS FROM PHASE 3 AEGIS-II TRIAL EVALUATING EFFICACY AND SAFETY OF CSL112
- THERE WERE NO MAJOR SAFETY OR TOLERABILITY CONCERNS WITH CSL112
- STUDY DID NOT MEET ITS PRIMARY EFFICACY ENDPOINT OF MACE REDUCTION AT 90 DAYS
News: CSL CSL Says Top-Line Results From Phase 3 Aegis-II Trial Evaluating Efficacy And Safety Of...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$257.96 |
Change
9.570(3.85%) |
Mkt cap ! $124.4B | |||
| Open | High | Low | Value | Volume |
| $252.00 | $258.31 | $251.10 | $287.5M | 1.116M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 127 | $257.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $257.96 | 35 | 4 |
View Market Depth
| Last trade - 15.38pm 18/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |